On 12 Nov 2026 Viatris closed at $20.67, +69.9% this year; market cap $23.74bn.
Health Care · Pharmaceuticals · NASDAQ · United States
Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars. It also provides drugs in various therapeutic areas covering various noncommunicable and infectious diseases, including cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, eye care, gastroenterology, immunology, oncology, and respiratory and allergy, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. In addition, the company offers medicines in the form of oral solid doses, injectables, and complex dosage forms to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. It distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies under the Lyrica, Lipitor, Celebrex, Viagra, Creon, Influvac, Wixela Inhub, EpiPen Auto-Injector, Fraxiparine, Yupelri, Norvasc, Amitiza, Effexor, Lipacreon, Zoloft, Xalabrands, Dymista, Xanax, and Breyna brands. The company has collaboration agreements with Mapi Pharma Ltd. to develop and commercialize long-acting glatiramer acetate depot products and additional products; Revance Therapeutics, Inc. to develop, manufacture, and commercialize a biosimilar to the branded biologic product, BOTOX; and Theravance Biopharma, Inc. to develop and commercialize revefenacin. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.
| Market cap | $23.74bn |
| P/E (trailing) | — |
| EPS (TTM) | $-0.53 |
| Beta | 0.87 |
| Dividend | $0.48 |
| Dividend yield | 2.32% |
| Ex-dividend date | 23 Nov 2026 |
| Latest report | 5 Nov 2026 |
| Next earnings | 4 Feb 2027 |
| YTD | +69.9% |
| 1Y | +94.4% |
| 3Y | +37.9% |
| 5Y | +12.6% |
| Year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | $14.30bn | $-3.51bn | $1.94bn |
| 2024 | $14.74bn | $-634.20m | $1.98bn |
| 2023 | $15.43bn | $54.70m | $2.33bn |
| 2022 | $16.26bn | $2.08bn | $2.51bn |
| 2021 | $17.89bn | $-1.27bn | $2.51bn |
We publish no single base value for Viatris. Our valuation methods put it between $18.99 and $30.80 a share. The valuation code's reason: no point fair value: the two anchors behind it compound the same growth rate and differ only in how they end — a perpetuity at the terminal rate against a multiple on the final year — so the midpoint between them measures terminal treatment rather than what the business is worth. The published range is the same reading with the false precision removed: read it as the span the method supports, and treat neither edge as a point estimate. See every method
Call and put prices: our price for each next to the market's.
Open in the dashboard · Run a full Desk Run
Data as of 12 Nov 2026. Not investment advice.